SOLENO ALERT: Bragar Eagel & Squire, P.C. is Investigating Soleno Therapeutics, Inc. on Behalf of Soleno Stockholders and Encourages Investors to Contact the Firm

(NASDAQ:SLNO), Bragar Eagel & Squire, P.C. Litigation Partner Brandon Walker Encourages Investors Who Suffered Losses In Soleno (SLNO) To Contact Him Directly To Discuss Their Options If you purchased or acquired stock in Soleno and would like to discuss your legal rights, call Bragar Eagel & Squire partner Brandon Walker or Marion Passmore directly at […]

SOLENO ALERT: Bragar Eagel & Squire, P.C. is Investigating Soleno Therapeutics, Inc. on Behalf of Soleno Stockholders and Encourages Investors to Contact the Firm

SOLENO ALERT: Bragar Eagel & Squire, P.C. is Investigating Soleno Therapeutics, Inc. on Behalf of Soleno Stockholders and Encourages Investors to Contact the Firm GlobeNewswire September 18, 2025 Bragar Eagel & Squire, P.C. Litigation Partner Brandon Walker Encourages Investors Who Suffered Losses In Soleno (SLNO) To Contact Him Directly To Discuss Their Options If you

Faruqi & Faruqi Reminds Flywire Investors of the Pending Class Action Lawsuit with a Lead Plaintiff Deadline of September 23, 2025 – FLYW

Faruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses Exceeding $50,000 In Flywire To Contact Him Directly To Discuss Their Options If you suffered losses exceeding $50,000 in Flywire between February 28, 2024 and February 25, 2025 and would like to discuss your legal rights, call Faruqi & Faruqi

CYTOKINETICS ALERT: Bragar Eagel & Squire, P.C. Announces that a Class Action Lawsuit Has Been Filed Against Cytokinetics, Incorporated and Encourages Investors to Contact the Firm

(NASDAQ:CYTK), Bragar Eagel & Squire, P.C. Litigation Partner Brandon Walker Encourages Investors Who Suffered Losses In Cytokinetics (CYTK) To Contact Him Directly To Discuss Their Options If you purchased or acquired common stock in Cytokinetics between December 27, 2023 and May 6, 2025 and would like to discuss your legal rights, call Bragar Eagel &

CYTOKINETICS ALERT: Bragar Eagel & Squire, P.C. Announces that a Class Action Lawsuit Has Been Filed Against Cytokinetics, Incorporated and Encourages Investors to Contact the Firm

CYTOKINETICS ALERT: Bragar Eagel & Squire, P.C. Announces that a Class Action Lawsuit Has Been Filed Against Cytokinetics, Incorporated and Encourages Investors to Contact the Firm GlobeNewswire September 18, 2025 Bragar Eagel & Squire, P.C. Litigation Partner Brandon Walker Encourages Investors Who Suffered Losses In Cytokinetics (CYTK) To Contact Him Directly To Discuss Their Options

Bunker Hill Announces Election of Directors and Results of Annual General Meeting

(TSX-V:BNKR),(OTC US:BHLL),(Other OTC:BHLL), KELLOGG, Idaho and VANCOUVER, British Columbia, Sept. 18, 2025 (GLOBE NEWSWIRE) — Bunker Hill Mining Corp. (“Bunker Hill” or the “Company“) (TSX-V: BNKR |OTCQB: BHLL) announces the voting results on matters considered at its annual meeting of stockholders held on September 18, 2025, in Kellogg, Idaho (the “Meeting“). At the Meeting, all

Bunker Hill Announces Election of Directors and Results of Annual General Meeting

Bunker Hill Announces Election of Directors and Results of Annual General Meeting GlobeNewswire September 18, 2025 KELLOGG, Idaho and VANCOUVER, British Columbia, Sept. 18, 2025 (GLOBE NEWSWIRE) — Bunker Hill Mining Corp. (“Bunker Hill” or the “Company“) (TSX-V: BNKR |OTCQB: BHLL) announces the voting results on matters considered at its annual meeting of stockholders held

Spectrum Pharmaceuticals (SPPI) and Assertio Holdings (ASRT) Investor Alert: 6-DAY DEADLINE in Securities Lawsuit- Hagens Berman

A New York federal court has re-opened the lead plaintiff process in theSpectrum Pharmaceuticals (SPPI) securities class action. This development offers a new opportunity for investors to represent the class after the previously appointed lead plaintiff was disqualified on August 4, 2025. The new deadline to apply is September 24, 2025. https://mma.prnewswire.com/media/2590203/Hagens_Berman_Sobol_Shapiro_LLP_Logo.jpg Importantly, (1) investors

NF-kB Inhibitors Market to Witness Accelerated Expansion Across the 7MM through 2034 | DelveInsight

The NF-kB inhibitors market is poised for growth driven by the increasing prevalence of cancer, autoimmune, and inflammatory diseases where NF-kB plays a central role. Additionally, the expected launch of emerging NF-kB inhibitors such as BioVie' bezisterim (NE3107), Entero Therapeutics' niclosamide (FW-UP), niclosamide (FW-ICI-AC), and others will further propel the NF-kB inhibitors market growth. DelveInsight's

Scroll to Top